Key result
Perioperative N-acetylcysteine cuts postoperative atrial fibrillation by ~43% versus placebo in CABG patients.
Why the study?
Postoperative atrial fibrillation is a common complication linked to adverse outcomes after CABG, and N-acetylcysteine may mitigate oxidative stress to reduce its incidence.
Does perioperative N-acetylcysteine reduce the incidence of postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting?
Meta-Analysis (n=648)
Does perioperative N-acetylcysteine reduce the incidence of postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting?
Effect estimate: OR 0.57 (95% CI 0.33 to 0.97)
Absolute Event Rate: 10.6% vs 17.4%
p-value: p=0.04
Perioperative administration of N-acetylcysteine effectively reduces the incidence of postoperative atrial fibrillation and shortens hospital length of stay in patients undergoing CABG.
Supports perioperative N-acetylcysteine to lower postoperative atrial fibrillation risk after CABG; reinforces meta-analytic evidence from randomized trials.
Background: As the prevalence of coronary artery disease rises, the demand for coronary artery bypass grafting (CABG) increases. A common complication after CABG is postoperative atrial fibrillation (POAF), which is linked to adverse clinical outcomes. N-acetylcysteine (NAC), an antioxidant, may mitigate oxidative stress and reduce the incidence of POAF. This meta-analysis aims to investigate the efficacy of NAC in preventing POAF after CABG. Methods: The meta-analysis was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We systematically searched multiple databases, including PubMed, Cochrane Library, ProQuest, and ScienceDirect, to identify relevant randomized controlled trials (RCTs). The intervention groups received perioperative NAC therapy, while the control groups received a placebo. The outcomes assessed were POAF incidence, all-cause mortality, and hospital length of stay (LOS). Review Manager 5.3 was used to conduct the meta-analysis. Results: Eleven RCTs involving 648 patients were included. The NAC group comprised 326 patients, while the control group comprised 322 patients. In the pooled analysis, patients in the NAC group had a significantly lower incidence of POAF (odds ratios (OR) = 0.57; 95% confidence intervals (CI) = 0.33 to 0.97; p = 0.04) and a shorter hospital LOS (weighted mean differences (WMD) = –0.66; 95% CI = –1.22 to –0.10; p = 0.02) compared to the control group. However, there was no significant difference in all-cause mortality. Conclusions: The perioperative administration of NAC can effectively reduce the incidence of POAF and hospital LOS in CABG patients. However, larger RCTs are needed to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Hanafy et al. (2024) conducted a meta-analysis in Coronary artery disease undergoing coronary artery bypass grafting (CABG) (n=648). N-acetylcysteine (NAC) vs. Placebo was evaluated on Incidence of postoperative atrial fibrillation (POAF) (OR 0.57, 95% CI 0.33 to 0.97, p=0.04). Perioperative administration of N-acetylcysteine significantly reduced the incidence of postoperative atrial fibrillation (OR 0.57) compared to placebo in patients undergoing coronary artery bypass grafting.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: